The Related Study Of CTL-DC As An Adjunctive Antiviral Therapy In Chronic Hepatitis B

The related study of CTL-DC as an adjunctive antiviral therapy in for 48 weeks and all the above measurement were observed. All data were processed by statistical method. 2. The activation of the DC: Peripheral blood mononuclear cell(PBMNC) were isolated by density gradient centrifugation and cultured under 37℃, 5% CO2 in vitro for 2 hours. Then adherent cells were collected and stimulated with cytokines for 7 days. Part of the cells was kept in order to stimulate CTL in vitro and the rest part was transfused back to patients’ body to activate CTL in vivo. 3. Virus specific CTL preparation: PBMNC from peripheral blood cells were isolated and cultivated for 2 hours. Then the non-adherent cells were collected and stimulated for 7 days with activated DC, virus antigen peptides and cytokines. Results: 1. After 48 weeks follow-up HBeAg seroconversion occurred in 4 cases among 56 patients(15 female, 41 male) without antiviral treatment; while it occurred in 14 cases among 64 patients(19 female, 45 male) with antiviral therapy. The difference between the two groups was statistically significant(P < 0.05) under X2 test. It is suggested that HBe Ag serological conversion rate is higher after antiviral treatment than spontaneous happened. 2. To patients who received nucleoside(acid) analogs antiviral treatment, their level of ALT, AST, HBVM and HBV DNA were detected and followed up for 48 weeks. Statistical analysis showed that there were no significant differences among the three nucleoside analogues group(adefovir dipivoxil, entecavir, telbivudine) with regard to their treatment outcome. 3. With CTL-DC helper cell therapy, anti HBV treatment effect can be enhanced in patients with nucleoside treatment. It can make HBV DNA in a low level of replication and decrease the titer of HBe Ag. It can also make HBe Ag/HBe Ab serological conversion occur in some individual patients. No adverse reaction of CTL-DC cell therapy has been found.Conclusion: 1.After antiviral treatment HBe Ag serological conversion rate is higher than spontaneous happened. 2. In the treatment of chronic hepatitis B antiviral treatment, statistical analysis showed no differences among three nucleoside(acid) analogues groups(entecavir, adefovir dipivoxil, telbivudine) with regard to quantities test of ALT, AST, HBsAg, HBe Ag, HBe Ab and HBVDNA. 3. CTL-DC cell therapy can enhance the therapeutic effect of hepatitis B antiviral treatment and improve liver function effectively. It can also lower HBV DNA replication level, gradually decrease HBe Ag quantitative level and improve HBe Ag serological conversion rate. As an auxiliary treatment method CTL-DC cell can improve the antiviral immunotherapy effect of nucleoside(acid) analogues in patients with chronic hepatitis B. It is proved to be a safe and feasible method.